Wanbury Ltd. Share Price

Wanbury Expands BerrySoft Baby Care Across States

Approval from the office of European Directorate - EDOM Approval for new product Rivaroxaban API, USFDA DMF Clearances.

Code BSE: 524212 NSE:

WANBURY: USFDA CLEARS MULTIPLE ANDAs WITH NO DMF DEFICIENCY LETTER 🇺🇸💊 • ✅ Wanbury has received "No DMF Deficiency Letter" from the USFDA for multiple ANDAs using its Metformin HCl API across different formulations • 🌍 The development strengthens the regulatory acceptance of Wanbury's Metformin API in the US market • 🇰🇷 The company also highlighted expansion of business opportunities in South Korea through filing of a DMF for another API • 🚀 Wanbury reiterated its commitment to supplying high-quality APIs to new international markets 🟢 Impact: Positive (USFDA regulatory clearance supports exports, enhances credibility, and can improve opportunities for API supplies to global generic drug manufacturers.)

WANBURY LIMITED:

CO. SUCCESSFULLY COMPLETES QUALITY INSPECTION BY TGA AT TANUKU, ANDHRA PRADESH; GMP CERTIFICATE WILL ENABLE SHIPPING OF ADDITIONAL 3 APIS; CONTINUES TO MAINTAIN CGMP COMPLIANCE.

WANBURY LIMITED: CO. ANNOUNCES LAUNCH OF FOUR NEW ANESTHETIC APIS AT TANUKU FACILITY; EXPECTED TO GENERATE REVENUE OF ₹100 CRORE IN FY 2026-27.

🚀Wanbury Climbing on Innovation. Watch out!

🧪 Product Launch – C RED: A next-gen Liposomal Iron formulation designed to manage anemia more effectively. ✅ Key Benefits of C RED: Enhanced absorption No metallic aftertaste Minimal digestive issues Safe for long-term use in pregnant women and iron-deficient patients 🌍 Market Response: Rolled out in Northern & Southern India, receiving strong doctor support and robust early sales. 📦 Expansion Plan: Pan-India distribution ramp-up in the next few months, driven by initial success. 🏭 Company Strength: Among India’s Top 50 pharma companies (ORG-IMS) with solid API exports and branded formulations. 📊 Ownership: Promoter holding stands at 39.76%, with growing non-institutional interest. What do you think of this one? Comment below.